Search research articles
Contact Us
Filters
Showing results (71-80 of 109) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2014
Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients
Marius E Mayerhoefer, Georgios Karanikas, Kurt Kletter, et al.
Blood
|
July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B Staber, Marco Herling, Mar Bellido, et al.
Blood Advances
|
August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
The Lancet. Oncology
|
September 24, 2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.
The New England Journal of Medicine
|
March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
John F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
Blood Advances
|
June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
Rakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Haematologica
|
April 26, 2015
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial
Ulrich Jaeger, Marek Trneny, Helen Melzer, et al.
Blood Advances
|
March 20, 2024
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
Marit Jalink, Chaja F Jacobs, Jahanzaib Khwaja, et al.
Blood
|
May 23, 2022
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
John F Seymour, Thomas J Kipps, Barbara F Eichhorst, et al.
The Lancet. Oncology
|
May 2, 2006
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Lorenz Trümper, Anders Osterborg, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 109) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2014
Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients
Marius E Mayerhoefer, Georgios Karanikas, Kurt Kletter, et al.
Blood
|
July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B Staber, Marco Herling, Mar Bellido, et al.
Blood Advances
|
August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
The Lancet. Oncology
|
September 24, 2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.
The New England Journal of Medicine
|
March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
John F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
Blood Advances
|
June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
Rakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Haematologica
|
April 26, 2015
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial
Ulrich Jaeger, Marek Trneny, Helen Melzer, et al.
Blood Advances
|
March 20, 2024
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
Marit Jalink, Chaja F Jacobs, Jahanzaib Khwaja, et al.
Blood
|
May 23, 2022
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
John F Seymour, Thomas J Kipps, Barbara F Eichhorst, et al.
The Lancet. Oncology
|
May 2, 2006
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Lorenz Trümper, Anders Osterborg, et al.
Page
of 11